BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28436941)

  • 21. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis.
    Cai G; Ma X; Zou W; Huang Y; Zhang J; Wang D; Chen B
    Gene; 2014 Aug; 546(1):117-23. PubMed ID: 23933413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
    Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
    Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.
    Biason P; Visentin M; Talamini R; Stopar A; Giorda G; Lucia E; Campagnutta E; Toffoli G
    Pharmacogenomics; 2012 Nov; 13(14):1609-19. PubMed ID: 23148637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
    [No Abstract]   [Full Text] [Related]  

  • 29. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease.
    Li Y; Kang S; Qin JJ; Wang N; Zhou RM; Sun HY
    Gynecol Oncol; 2012 Sep; 126(3):455-9. PubMed ID: 22683585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women.
    Shi TY; Jiang Z; Jiang R; Yin S; Wang MY; Yu KD; Shao ZM; Sun MH; Zang R; Wei Q
    Tumour Biol; 2015 Sep; 36(9):6919-27. PubMed ID: 25854172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
    Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.
    Carron J; Brito AB; Torelli AC; Oliveira C; Derchain SF; Lima CS; Lourenço GJ
    Med Oncol; 2016 Oct; 33(10):112. PubMed ID: 27586145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
    Xie X; Yang M; Ding Y; Yu L; Chen J
    Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.
    Zeng Y; Li TL; Zhang HB; Deng JL; Zhang R; Sun H; Wan ZR; Liu YZ; Zhu YS; Wang G
    Pharmacogenomics; 2019 Feb; 20(3):179-188. PubMed ID: 30672383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Gynecol Oncol; 2011 Sep; 122(3):554-9. PubMed ID: 21714991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.